Trial-to-trial variability in survival by cytogenetic group
| Trial . | Group . | Median survival, wk (95% CI) . | ||||
|---|---|---|---|---|---|---|
| Overall . | Inv(16) or t(8;21) . | − 5/− 7 . | Other abnormal . | Normal . | ||
| IA | IA | 77 (56-132) | — (69 to —) | 1 (0.4, to —) | 75 (52-196) | 85 (29-264) |
| n = 84 | n = 15 | n = 3 | n = 27 | n = 39 | ||
| IA + G-CSF (G) | IA | 86 (58-123) | 269 (83 to —) | 34 (7 to —) | 64 (40-136) | 86 (51-140) |
| n = 144 | n = 18 | n = 9 | n = 36 | n = 81 | ||
| IA + G + ATRA | IA | 83 (41 to —) | 65.5 (0.4 to —) | 5 (— to —) | 68 (34 to —) | 83 (41 to —) |
| n = 25 | n = 4 | n = 1 | n = 4 | n = 16 | ||
| IA ± lisofylline | IA | 53 (44-88) | 115 (32 to —) | 22 (5-36) | 88 (51-178) | 63 (49-145) |
| (randomized) | n = 69 | n = 10 | n = 16 | n = 18 | n = 25 | |
| FAI ± G and/or ATRA | FA | 30 (23-40) | 78 (2 to —) | 15 (7-26) | 37 (17-59) | 47 (32-72) |
| (randomized) | n = 248 | n = 5 | n = 76 | n = 74 | n = 93 | |
| FAI + G or ATRA | FA | 28 (18-39) | — (— to —) | 18 (13-33) | 28 (12-61) | 53 (33-81) |
| (not randomized) | n = 136 | n = 1 | n = 70 | n = 42 | n = 23 | |
| FA or FLAG | FA | 32 (27-46) | — (— to —) | 26 (17-32) | 26 (12-51) | 49 (35-99) |
| n = 216 | n = 8 | n = 73 | n = 62 | n = 73 | ||
| TA | TA | 38 (30-48) | 64 (17 to —) | 27 (22-42) | 43 (28-80) | 53 (38-86) |
| n = 98 | n = 3 | n = 35 | n = 28 | n = 32 | ||
| CAT | TA | 45 (35-58) | — (— to —) | 31 (17-48) | 41 (23-71) | 52 (32 to —) |
| n = 259 | n = 18 | n = 57 | n = 53 | n = 131 | ||
| Trial . | Group . | Median survival, wk (95% CI) . | ||||
|---|---|---|---|---|---|---|
| Overall . | Inv(16) or t(8;21) . | − 5/− 7 . | Other abnormal . | Normal . | ||
| IA | IA | 77 (56-132) | — (69 to —) | 1 (0.4, to —) | 75 (52-196) | 85 (29-264) |
| n = 84 | n = 15 | n = 3 | n = 27 | n = 39 | ||
| IA + G-CSF (G) | IA | 86 (58-123) | 269 (83 to —) | 34 (7 to —) | 64 (40-136) | 86 (51-140) |
| n = 144 | n = 18 | n = 9 | n = 36 | n = 81 | ||
| IA + G + ATRA | IA | 83 (41 to —) | 65.5 (0.4 to —) | 5 (— to —) | 68 (34 to —) | 83 (41 to —) |
| n = 25 | n = 4 | n = 1 | n = 4 | n = 16 | ||
| IA ± lisofylline | IA | 53 (44-88) | 115 (32 to —) | 22 (5-36) | 88 (51-178) | 63 (49-145) |
| (randomized) | n = 69 | n = 10 | n = 16 | n = 18 | n = 25 | |
| FAI ± G and/or ATRA | FA | 30 (23-40) | 78 (2 to —) | 15 (7-26) | 37 (17-59) | 47 (32-72) |
| (randomized) | n = 248 | n = 5 | n = 76 | n = 74 | n = 93 | |
| FAI + G or ATRA | FA | 28 (18-39) | — (— to —) | 18 (13-33) | 28 (12-61) | 53 (33-81) |
| (not randomized) | n = 136 | n = 1 | n = 70 | n = 42 | n = 23 | |
| FA or FLAG | FA | 32 (27-46) | — (— to —) | 26 (17-32) | 26 (12-51) | 49 (35-99) |
| n = 216 | n = 8 | n = 73 | n = 62 | n = 73 | ||
| TA | TA | 38 (30-48) | 64 (17 to —) | 27 (22-42) | 43 (28-80) | 53 (38-86) |
| n = 98 | n = 3 | n = 35 | n = 28 | n = 32 | ||
| CAT | TA | 45 (35-58) | — (— to —) | 31 (17-48) | 41 (23-71) | 52 (32 to —) |
| n = 259 | n = 18 | n = 57 | n = 53 | n = 131 | ||
CI, confidence interval; IA, idarubicin + ara-C; G-CSF, granulocyte colony-stimulating factor; ATRA, all-trans retinoic acid; IA, idarubicin + ara-C; FAI, fludarabine + ara-C + idarubicin; FA, fludarabine + ara-C; FLAG, FA + G-CSF; TA, topotecan + ara-C; CAT, cyclophosphamide + G-CSF.